Blog · Pricing · Published 2026-08-09
Tirzepatide vs Semaglutide in 2026: Results, Side Effects, and What Each Costs Compounded
Tirzepatide produced meaningfully more weight loss than semaglutide in the one head-to-head trial — SURMOUNT-5 reported roughly 20.2% vs 13.7% average body-weight reduction at 72 weeks — with broadly similar GI-dominant side-effect profiles. On price, the 2026 compounded floors sit $41 apart: semaglutide from $145/month effective and tirzepatide from $186/month effective (both NexLife 12-month equivalents, dose-flat), against brand self-pay at $349 flat (Wegovy) and $299–$449 by dose (Zepbound). The honest summary: tirzepatide buys more average efficacy for more money; semaglutide remains the value baseline with a decade-deeper safety record.
Efficacy: what the head-to-head actually showed
SURMOUNT-5 randomized adults with obesity to maximum-tolerated doses of each drug — the comparison every "which is stronger" thread wants. Tirzepatide's dual GIP/GLP-1 mechanism delivered ~20.2% average loss versus semaglutide's ~13.7%, and higher proportions reached the 15%-plus and 20%-plus thresholds. Two qualifiers keep it honest: averages hide wide individual spread (plenty of semaglutide patients out-lose plenty of tirzepatide patients), and 2026 added a wrinkle — Wegovy HD's 7.2 mg dose narrowed the gap (~20.7% in STEP-UP) without a direct trial against tirzepatide 15 mg. Our research journal logs the trial summaries with full qualifiers.
Side effects and tolerability
Both are GI-first drugs: nausea, constipation, diarrhea, and reflux dominate real-world reports for each, typically worst during dose escalation. Discontinuation-for-adverse-events ran modestly higher on tirzepatide in SURMOUNT-5, consistent with more drug effect overall; both carry the class boxed warning (thyroid C-cell tumors in rodents) and the standard pancreatitis and gallbladder cautions. For compounded versions specifically, the added variable isn't the molecule — it's the vial: concentration changes between fills drive the dosing-error reports, which is why the label-math routine applies equally to both molecules.
The cost decision, normalized
Captured 2026 effective-monthly floors and fields: semaglutide $145–$297 (six ranked programs); tirzepatide $186–$449 (five ranked). The $41/month floor gap ($492/year) is the price of the average efficacy difference — a defensible spend for some, unnecessary for others who respond well to semaglutide. Decision inputs that outrank the averages: your response at 12–16 weeks, tolerability, and whether your program's pricing is dose-flat or scales with titration. Medicare-eligible readers: run the ~$50 coverage check before paying cash for either.
Frequently asked questions
Which is better for weight loss, tirzepatide or semaglutide?
In the only head-to-head trial (SURMOUNT-5), tirzepatide averaged ~20.2% body-weight loss vs ~13.7% for semaglutide at 72 weeks. Individual responses vary widely, and semaglutide's new 7.2 mg dose (~20.7% in STEP-UP) narrows the gap without a direct comparison.
Is tirzepatide or semaglutide cheaper compounded?
Semaglutide — captured floors are $145/month effective vs $186 for tirzepatide (both NexLife 12-month equivalents, dose-flat), a $41/month gap. Fields run $145–$297 and $186–$449 respectively.
Are the side effects different?
Similar in kind — GI symptoms dominate both, worst during titration. Adverse-event discontinuation ran modestly higher on tirzepatide in the head-to-head; both share the class boxed warning and pancreatitis/gallbladder cautions.
Can I switch between them?
Yes, with a prescriber managing the transition — dose equivalence isn't one-to-one, and pricing structures differ by program. The switching checklist covers records, timing, and refund terms.
Primary sources
SURMOUNT-5 and STEP-UP topline results (NEJM / company releases); FDA labeling for Zepbound and Wegovy; captured compounded pricing per the methodology. See the research journal for trial summaries.
Update (2026-08-10): Novo's CagriSema missed tirzepatide's blood-sugar control in a head-to-head type-2-diabetes readout disclosed with Q2 results — next-generation context in the newsroom.
Independent & transparent
Independently operated by US Peptides Partners LLC. Rankings are editorial, computed from published pricing under the methodology, and are not for sale. Outbound provider links carry referral-tracking tags; no arrangement changes a ranking — if a provider out-scores the current leader on captured figures, the ranking changes.